Position of the Transparency Council – Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant)
At its meeting on 12 November 2024, the Transparency Council adopted position No. 120/2024 on the evaluation of the drug Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant) for the indication: passive protection in infants from birth to 6 months of age after maternal vaccination during pregnancy